enVVeno Medical Corp
Change company Symbol lookup
Select an option...
NVNO enVVeno Medical Corp
ST Sensata Technologies Holding PLC
ZTS Zoetis Inc
AZZ AZZ Inc
CRM Salesforce Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Postmarket

Last Trade
Delayed
$3.91
-0.205 (-4.98%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$4.12
Day's Change
0.245 (6.33%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
4.14
Day's Low
3.81
Volume
(Below Average)
Volume:
17,677

10-day average volume:
19,931
17,677

Display:

Providers:

UpdateCancel
6 providers
May 02, 2022
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data - Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll...(Accesswire)

April 11, 2022
enVVeno Medical Announces New U.S. VenoValve(R) Patent

- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg (Accesswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.